

Fabrizio Pane

List of Publications by Citations

Source: <https://exaly.com/author-pdf/10723494/fabrizio-pane-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

177
papers

10,427
citations

49
h-index

101
g-index

181
ext. papers

11,769
ext. citations

4.1
avg, IF

4.99
L-index

#	Paper	IF	Citations
177	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013 , 122, 872-84	2.2	1413
176	Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6041-51	2.2	1019
175	Ruxolitinib versus standard therapy for the treatment of polycythemia vera. <i>New England Journal of Medicine</i> , 2015 , 372, 426-35	59.2	533
174	Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2006 , 12, 7374-9	12.9	405
173	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. <i>Blood</i> , 2011 , 118, 1208-15	2.2	395
172	ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4100-9	2.2	308
171	Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. <i>Blood</i> , 2008 , 112, 3330-8	2.2	306
170	Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 553-61	9.7	301
169	IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5202-7	2.2	245
168	Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 424-30	2.2	235
167	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020 , 7, e737-e745	14.6	223
166	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). <i>Blood</i> , 2009 , 114, 2159-67	2.2	180
165	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. <i>Haematologica</i> , 2007 , 92, 1173-9	6.6	177
164	Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. <i>Blood</i> , 2009 , 114, 4933-8	2.2	176
163	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. <i>Blood</i> , 2005 , 105, 3434-41	2.2	161
162	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. <i>Blood</i> , 2009 , 113, 4497-504	2.2	158
161	Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. <i>Blood</i> , 2006 , 108, 1999-2005	2.2	146

160	CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1295-300	2.2	143
159	Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2014 , 123, 2094-101	2.2	141
158	Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 1829-35	8.9	123
157	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. <i>Haematologica</i> , 2016 , 101, 821-9	6.6	115
156	Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1721-7	1.9	109
155	Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. <i>Clinical Chemistry</i> , 2004 , 50, 1205-13	5.5	109
154	Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. <i>Blood</i> , 2008 , 112, 3847-55	2.2	95
153	Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. <i>Blood</i> , 2008 , 112, 1876-85	2.2	94
152	Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. <i>Blood</i> , 2006 , 107, 473-9	2.2	93
151	Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. <i>Cancer</i> , 2014 , 120, 1002-9	6.4	92
150	MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2002 , 100, 974-81	2.2	92
149	BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. <i>Oncogene</i> , 2002 , 21, 8652-67	9.2	86
148	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2012 , 120, 761-7	2.2	85
147	Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2004 , 104, 4245-51	2.2	85
146	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. <i>Haematologica</i> , 2013 , 98, 193-200	6.6	83
145	Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. <i>Blood</i> , 2011 , 117, 5591-9	2.2	78
144	Monitoring treatment of chronic myeloid leukemia. <i>Haematologica</i> , 2008 , 93, 161-9	6.6	78
143	Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. <i>Clinical Cancer Research</i> , 2006 , 12, 3037-42	12.9	78

142	High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. <i>Blood</i> , 2011 , 117, 3353-62	2.2	75
141	Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. <i>Haematologica</i> , 2008 , 93, 1792-6	6.6	74
140	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2011 , 117, 6793-800	3.3	66
139	NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. <i>Haematologica</i> , 2008 , 93, 439-42	6.6	66
138	IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. <i>PLoS ONE</i> , 2012 , 7, e40934	3.7	60
137	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2004 , 103, 2284-90	2.2	60
136	The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. <i>Haematologica</i> , 2009 , 94, 205-12	6.6	54
135	Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. <i>Blood</i> , 2009 , 114, 4939-43	2.2	54
134	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. <i>Blood</i> , 2009 , 113, 3428-34	2.2	53
133	The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. <i>American Journal of Hematology</i> , 2017 , 92, 797-805	7.1	52
132	Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. <i>Lancet Haematology</i> , 2020 , 7, e226-e237	14.6	52
131	CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. <i>Clinical Cancer Research</i> , 2011 , 17, 7413-23	12.9	52
130	Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. <i>Cancer</i> , 2002 , 94, 2416-25	6.4	52
129	Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. <i>Haematologica</i> , 2011 , 96, 1457-61	6.6	49
128	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. <i>Haematologica</i> , 2008 , 93, 770-4	6.6	49
127	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. <i>Haematologica</i> , 2007 , 92, 101-5	6.6	49
126	Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. <i>Haematologica</i> , 2012 , 97, 907-14	6.6	48
125	Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2748-54	2.2	48

124	BCR/ABL mRNA and the P210BCR/ABL Protein Are Downmodulated by Interferon- γ in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 1999 , 94, 2200-2207	2.2	43
123	SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. <i>Blood</i> , 2011 , 118, 3634-3644	2.2	41
122	Amyloid in bone marrow smears of patients affected by multiple myeloma. <i>Annals of Hematology</i> , 2010 , 89, 469-74	3	40
121	Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. <i>Journal of Clinical Oncology</i> , 2008 , 26, 106-11	2.2	40
120	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019 , 3, 4280-4290	7.8	40
119	The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. <i>Haematologica</i> , 2010 , 95, 1683-90	6.6	39
118	The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. <i>Haematologica</i> , 2010 , 95, 1415-9	6.6	39
117	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019 , 104, 1589-1596	6.6	38
116	Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. <i>Clinical Chemistry</i> , 2013 , 59, 938-48	5.5	38
115	Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. <i>Haematologica</i> , 2003 , 88, 1296-303	6.6	38
114	Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. <i>European Journal of Haematology</i> , 2016 , 97, 192-200	3.8	37
113	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. <i>Blood</i> , 2020 , 135, 534-541	2.2	37
112	Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. <i>International Journal of Hematology</i> , 2014 , 99, 516-24	2.3	35
111	Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures. <i>Radiology</i> , 2014 , 272, 262-74	20.5	34
110	Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. <i>Haematologica</i> , 2008 , 93, 1814-21	6.6	34
109	Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. <i>Journal of Clinical Oncology</i> , 2006 , 24, 454-9	2.2	34
108	Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. <i>Annals of Hematology</i> , 2017 , 96, 549-558	3	32
107	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. <i>Haematologica</i> , 2015 , 100, 1146-50	6.6	29

106	Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. <i>Hematological Oncology</i> , 2006 , 24, 196-204	1.3	28
105	Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study. <i>Radiology</i> , 2009 , 251, 574-82	20.5	27
104	Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. <i>Clinical Cancer Research</i> , 2009 , 15, 1059-63	12.9	27
103	¹⁸ F-FDG PET/CT, ^{99m} Tc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study. <i>Clinical Nuclear Medicine</i> , 2015 , 40, 303-8	1.7	25
102	Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. <i>Leukemia Research</i> , 2014 , 38, 236-42	2.7	22
101	Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype. <i>Hematological Oncology</i> , 2007 , 25, 1-5	1.3	22
100	Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. <i>BMC Gastroenterology</i> , 2014 , 14, 31	3	21
99	Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2006 , 167, 97-102		20
98	Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. <i>American Journal of Hematology</i> , 2018 , 93, 58-64	7.1	19
97	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. <i>Haematologica</i> , 2016 , 101, 1200-1207	6.6	19
96	BCR/ABL transcripts and leukemia phenotype: an unsolved puzzle. <i>Leukemia and Lymphoma</i> , 1997 , 26, 281-6	1.9	17
95	Cytological and histological detection of amyloid deposits in bone marrow of patients affected by multiple myeloma. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2304-7	1.9	16
94	Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2008 , 93, 1017-24	6.6	16
93	FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype. <i>American Journal of Hematology</i> , 2009 , 84, 532-5	7.1	15
92	In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. <i>BMC Cancer</i> , 2016 , 16, 572	4.8	15
91	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018 , 97, 95-100	3	14
90	Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2010 , 1804, 1974-87	4	14
89	WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene. <i>Oncotarget</i> , 2015 , 6, 28223-37	3.3	13

88	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017 , 102, 1530-1536	6.6	12
87	Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1018-24	4.7	12
86	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. <i>Blood</i> , 2010 , 116, 359-359	2.2	12
85	Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma. <i>Annals of Hematology</i> , 2020 , 99, 127-135	3	12
84	Secondary syphilis mimicking malignancy: A case report and review of literature. <i>Journal of Infection and Chemotherapy</i> , 2017 , 23, 576-578	2.2	11
83	24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).. <i>Blood</i> , 2009 , 114, 337-337	2.2	11
82	Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 981-6	4.7	10
81	Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2016 , 91, 617-22	7.1	10
80	Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL. <i>Blood</i> , 2019 , 133, 498-501	2.2	10
79	Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma. <i>Annals of Hepatology</i> , 2017 , 16, 198-206	3.1	9
78	Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support. <i>Supportive Care in Cancer</i> , 2019 , 27, 1587-1588	3.9	8
77	Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. <i>Annals of Hematology</i> , 2013 , 92, 179-83	3	8
76	Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line. <i>Blood</i> , 2008 , 112, 185-185	2.2	8
75	New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia. <i>Expert Review of Hematology</i> , 2009 , 2, 297-303	2.8	7
74	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , 2016 , 128, 3070-3070	2.2	7
73	The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data. <i>European Journal of Haematology</i> , 2020 , 105, 3-15	3.8	6
72	Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. <i>Leukemia and Lymphoma</i> , 2009 , 50, 114-8	1.9	6
71	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018 , 132, 44-44	2.2	6

70	Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper. <i>Cancer Medicine</i> , 2020 , 9, 2960-2970	4.8	5
69	Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019 , 11, e2019025	3.2	5
68	Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 90, 181-9	7	4
67	Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors. <i>Blood</i> , 2019 , 134, 496-496	2.2	4
66	Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.. <i>Blood</i> , 2009 , 114, 2205-2205	2.2	4
65	Detection of BCR/ABL rearrangements in adult acute lymphoblastic leukemia using a highly sensitive interphase fluorescence in situ hybridization method (D-FISH). <i>The Hematology Journal</i> , 2001 , 2, 54-60		4
64	Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. <i>Frontiers in Oncology</i> , 2021 , 11, 642005	5.3	4
63	Acute immune toxicity during anti-thymocyte globulin: That's CARPA!. <i>American Journal of Hematology</i> , 2018 , 93, E22-E24	7.1	3
62	International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a GIMEMA and HOVON Study. <i>Blood</i> , 2018 , 132, 1750-1750	2.2	3
61	Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. <i>Blood</i> , 2018 , 132, 661-661	2.2	3
60	BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing?. <i>Blood</i> , 2015 , 126, 346-346	2.2	3
59	A critical history of chronic myeloid leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014 , 6, e2014010	3.2	2
58	JAK2V617F mutation persists in blasts and mature cells of transformed JAK2V617F-positive-myeloproliferative neoplasia: a European Leukemia Net (ENL) study. <i>American Journal of Hematology</i> , 2010 , 85, 383-6	7.1	2
57	Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group. <i>Blood</i> , 2018 , 132, 45-45	2.2	2
56	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. <i>Blood</i> , 2018 , 132, 458-458	2.2	2
55	A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 2092-2092	2.2	2
54	Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial. <i>Blood</i> , 2019 , 134, 4145-4145	2.2	2
53	Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.. <i>Blood</i> , 2005 , 106, 375-375	2.2	2

52	The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.. <i>Blood</i> , 2009 , 114, 2192-2192	2.2	2
51	One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience. <i>Blood</i> , 2018 , 132, 1732-1732	2.2	1
50	Better Molecular Response (MR) to Imatinib (IM) in Early Chronic Phase (CP) Versus Late CP Chronic Myeloid Leukemia (CML) Patients (pts) in Complete Cytogenetic Response (CCR): A Comparison at 24 Months of 2 Clinical Trials of the GIMEMA Working Party on CML on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML). <i>Blood</i> , 2005 , 106, 1096-1096	2.2	1
49	Chronic Eosinophilic Leukaemia (CEL) with FIP1L1-PDGFRalpha Rearrangement (F/P): The Response to Imatinib (IM) Is Durable. A Report of 33 Patients with A Follow Up of 30 to 92 Months.. <i>Blood</i> , 2009 , 114, 3894-3894	2.2	1
48	Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. <i>British Journal of Haematology</i> , 2018 , 182, 279-284	4.5	1
47	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. <i>Frontiers in Oncology</i> , 2021 , 11, 739171	5.3	1
46	Neutrophilic-chronic myeloid leukemia 2002 , 94, 2416		1
45	Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. <i>Blood</i> , 2020 , 136, 17-18	2.2	0
44	Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. <i>Blood</i> , 2015 , 126, 2792-2792	2.2	0
43	Eltrombopag for Prolonged Post-Transplant Hyporigenerative Cytopenias. <i>Blood</i> , 2018 , 132, 5711-5711	2.2	0
42	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. <i>Blood</i> , 2010 , 116, 1230-1230	2.2	0
41	Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe. <i>Blood</i> , 2010 , 116, 894-894	2.2	0
40	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020 , 136, 23-25	2.2	
39	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020 , 136, 47-48	2.2	
38	Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in NOVEL Agents' Era. <i>Blood</i> , 2020 , 136, 2-3	2.2	
37	Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma. <i>Blood</i> , 2020 , 136, 2-2	2.2	
36	Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone. <i>Blood</i> , 2020 , 136, 18-18	2.2	
35	Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Transplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2020 , 136, 26-27	2.2	

- 34 Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. *Blood*, **2020**, 136, 49-50 2.2
- 33 First Line Treatment with Hydroxyurea in Patients with Polycitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. *Blood*, **2020**, 136, 43-44 2.2
- 32 Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma. *Blood*, **2020**, 136, 1-1 2.2
- 31 Imatinib in the Treatment of CML Patients ≥ 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.. *Blood*, **2004**, 104, 2935-2935 2.2
- 30 Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. *Blood*, **2005**, 106, 1100-1100 2.2
- 29 The Quantitative Assessment of WT1 Allows To Distinguish between Primary and Secondary or Reactive Hypereosinophilia.. *Blood*, **2005**, 106, 3251-3251 2.2
- 28 Chromosome Abnormalities in Multiple Myeloma Patients: Impact on Prognosis and Survival.. *Blood*, **2006**, 108, 5054-5054 2.2
- 27 Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.. *Blood*, **2006**, 108, 2158-2158 2.2
- 26 FIP1L1-PDGFRalpha Positive Hypereosinophilic Syndrome (HES). The Response to Imatinib (IM) Is Durable. A Report of 21 Patients with a Follow-Up of 12 to 67 Months.. *Blood*, **2006**, 108, 2700-2700 2.2
- 25 Down-Modulation of Shp1 and Hsp70 Provides a Survival Advantage to the Ph+ Cells of CML Patients Additive to That Related to the Oncogenic BCR/ABL Protein and May Account for Resistance to Ima Treatment.. *Blood*, **2007**, 110, 1014-1014 2.2
- 24 Adding Hydroxyurea in Combination with Ruxolitinib Improves Clinical Responses in Hyperproliferative Forms of Myelofibrosis. *Blood*, **2018**, 132, 4290-4290 2.2
- 23 Pegfilgrastim Versus Filgrastim in the Management of Therapy-Related Neutropenia in Relapsed and Refractory Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone. *Blood*, **2018**, 132, 5905-5905 2.2
- 22 Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma. *Blood*, **2018**, 132, 5648-5648 2.2
- 21 Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study. *Blood*, **2019**, 134, 4188-4188 2.2
- 20 Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial. *Blood*, **2015**, 126, 4046-4046 2.2
- 19 The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy. *Blood*, **2016**, 128, 3097-3097 2.2
- 18 Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib.. *Blood*, **2009**, 114, 2211-2211 2.2
- 17 PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party.. *Blood*, **2009**, 114, 12-12 2.2

- 16 Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients.. *Blood*, **2009**, 114, 2212-2212 2.2
- 15 Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity.. *Blood*, **2009**, 114, 3283-3283 2.2
- 14 Preferential Nuclear Accumulation of JAK2V617F In CD34+ but Not Granulocytic, Megakaryocytic or Erythroid Cells of Patients with Philadelphia-Negative Myeloproliferative Neoplasia. *Blood*, **2010**, 116, 4089-4089 2.2
- 13 First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, Deep and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party. *Blood*, **2010**, 116, 2279-2279 2.2
- 12 Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party. *Blood*, **2010**, 116, 2279-2279 2.2
- 11 Specific Drug Transporter Genotypes Are Significantly Associated with Increased Rates of Major and Complete Molecular Responses In Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Imatinib [A TOPS Correlative Substudy]. *Blood*, **2010**, 116, 670-670 2.2
- 10 Whole Transcriptome Resequencing of Paired Diagnosis-Relapse BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Samples Reveals the Loss of Cell Cycle Regulation as the Main Mechanism Responsible for Leukemia Progression.. *Blood*, **2010**, 116, 1024-1024 2.2
- 9 JAK2V617F Mutation Persists IN Blasts and Mature CELLS of Transformed-JAK2V617F-POSITIVE-MYELOPROLIFERATIVE Neoplasia: A European LEUKEMIA NET (ENL) STUDY. *Blood*, **2010**, 116, 4090-4090 2.2
- 8 Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus.. *Blood*, **2010**, 116, 1670-1670 2.2
- 7 Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2010**, 116, 1677-1677^{2.2}
- 6 The Elevated Expression of FBP1, a Key-Enzyme of Gluconeogenesis Gene, Is Associated to High Sokal Risk In Chronic Myeloid Leukemia Patients.. *Blood*, **2010**, 116, 3399-3399 2.2
- 5 Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107). *Blood*, **2010**, 116, 510-510 2.2
- 4 Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro. *Blood*, **2012**, 120, 370-370 2.2
- 3 4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. *Blood*, **2013**, 122, 4000-4000 2.2
- 2 Thrombosis History and Relationship With Low Thrombocytosis, Leukocytosis, and Other Characteristics At Diagnosis In 977 Essential Thrombocythemia Patients A Multivariate Analysis Of The Registro Italiano Trombocitemie (RIT). *Blood*, **2013**, 122, 2829-2829 2.2
- 1 The Interferon Score Towards Interferon Alpha Tailored Therapy In Essential Thrombocythemia. *Blood*, **2013**, 122, 4073-4073 2.2